Optimization of treatment of patients with follicular ovarian cysts

The reason of tumor-like ovarian cysts are functional disorders of the hypothalamic-pituitary-ovarian axis which leads to hyperestrogenocity. Medical preparations containing indole-3-carbinol have an evident antiestrogenic effect. The objective: to study the efficacy of using Mastofemin for the treatment of patients with ovarian cysts. Patients and methods. The study involved 110 patients of reproductive age, 30 of them were healthy and were included in Group I. There were 38 women with follicular cysts in Group II whom 30 мg of ethinylestradiol-containing combined oral contraceptives in cyclic regimen for 3 months were prescribed. There were 42 patients in Group III who were additionally to combined oral contraceptives prescribed Mastofemin for 1 capsule 2 times daily. Results. The presence of combined breast pathology and clinical symptoms associated with hyperestrogenocity has been noted in patients with follicular ovarian cysts. The operative treatment due to the lack of effectiveness of the conservative approach was performed in 21.1% of patients in Group II and 7.1% of women in Group III. There was no recurrence of ovarian cysts during further observation within six months in the main Group of patients receiving Mastofemin. 10.5% of women have the reappeared ovarian retention cysts in the Group II. Conclusion. The use of Mastophemin in addition to combined oral contraceptives for treating women with follicular ovarian cysts contributed to increased compliance and therapeutic efficacy. Key words: ovarian follicular cysts, indole-3-carbinol, Mastofemin.